Subscribe today to receive notice of our latest thought leadership, articles, blogs and updates.
Clinical Connection
Thought leadership on the clinical impact on workers' compensation and auto no-fault.
Recent blog posts
|
August 11, 2023 · Clinical Team
FDA approves additional over-the-counter naloxone products Read more... |
|
|
July 18, 2023 · Clinical Team
The 2Q 2023 Brand-Generic Pipeline update Read more... |
|
|
July 06, 2023 · Clinical Team
Extended-release Brixadi has been approved by the FDA for subcutaneous injection in patients recovering from Opioid Use Disorder as part of their treatment plan. Read more... |
|
|
May 08, 2023 · Clinical Team
The U.S. Food and Drug Administration (FDA) announced that Teva Pharmaceuticals USA voluntarily recalled specific lots of various strengths of fentanyl buccal tablets at the consumer level. Read more... |
|
|
May 02, 2023 · Clinical Team
On March 29, 2023, the U.S. Food and Drug Administration (FDA) approved Narcan® (naloxone hydrochloride) 4 mg Nasal Spray for over-the-counter (OTC), nonprescription, use. Read more... |
|
|
May 01, 2023 · Clinical Team
Akorn Operating Company LLC filed Chapter 7 bankruptcy and the company has ceased all operations, including the discontinuation of the quality activities of these marketed drug products. Read more... |
|
|
April 20, 2023 · Clinical Team
On April 21, 2023, the ODG Drug Formulary (Appendix A) status will change for several medications within the topical analgesic and nonsteroidal anti-inflammatory (NSAID) classes. Read more... |
|
|
April 06, 2023 · Clinical Team
Our Brand–Generic Pipeline lists new medications approved by the U.S. FDA and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. The Brand–Generic Pipeline for Q1 2023 is now available -- read it here. Read more... |
Page 2 of 8
